KREBSBEHANDLUNG MIT NALTREXON UND EINEM CANNABINOID

Patent europeic · EP3937914 · Stritgà

Inscripziun en il register

Numer da publicaziun
EP3937914
Numer da la dumonda
EP20712673
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
Stritgà
Scrittira da patent
Concedì
Annunzià
13-03-2020
Publitgà
19-01-2022
Concedì
09-08-2023
Stritgà
23-10-2024
Motiv
Taxa annuala betg pajada
Classas IPC
A61K 31/05 (2006.01)
A61K 31/08 (2006.01)
A61K 31/192 (2006.01)
A61K 31/352 (2006.01)
A61K 31/485 (2006.01)
A61K 45/06 (2006.01)
A61P 35/00 (2006.01)
A61K 31/555 (2006.01)
A61K 31/7068 (2006.01)
Prioritad
GB 201903546 15.03.2019
Dumonda PCT
PCT/GB2020/050638 13.03.2020
Publicaziun PCT
WO2020/188255 24.09.2020
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 23-10-2024

    Stritgà, taxa betg pajada

    Status of protective title
    Active → Cancelled
    Cancellation date
    23.10.2024
    Cause for cancellation
    Non-payment of renewal fee

    Published in Swissreg on 23.10.2024

  2. 19-06-2024

    Midada

    Published in Swissreg on 19.06.2024

  3. 09-08-2023

    Concedì

    Published in Swissreg on 09.08.2023

Partidas

Possessur

LDN Pharma Limited

45 Gresham Street, London EC2V 7BG, GB

Inventur

DALGLEISH, Angus

London EC2V 7BG, GB

LIU, Wai

London EC2V 7BG, GB

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.